Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resilire: Retinoic Acid and Immunotherapy in HER2-Negative Breast Cancer
NCT06731140Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Feb 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tretinoin in breast cancer, sponsored by Fudan University. Started Feb 2025; status: recruiting.
02
Drugs
tretinoin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06731140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06731140.